期刊文献+

Primary hepatic leiomyosarcoma with liver metastasis of rectal cancer 被引量:2

Primary hepatic leiomyosarcoma with liver metastasis of rectal cancer
暂未订购
导出
摘要 Primary hepatic leiomyosarcoma is a particularly rare tumor with a poor prognosis. Curative resection is currently the only effective treatment, and the efficacy of chemotherapy is unclear. This represents the first case report of a patient with primary hepatic leiomyosarcoma co-existing with metastatic liver carcinoma. We present a 59-year-old man who was diagnosed preoperatively with rectal cancer with multiple liver metastases. He underwent a curative hepatectomy after a series of chemotherapy regimens with modified FOLFOX6 consisting of 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab, FOLFIRI consisting of 5-fluorouracil, leucovorin and irinotecan plus bevacizumab, and irinotecan plus cetuximab. One of the liver tumors showed a different response to chemotherapy and was diag-nosed as a leiomyosarcoma following histopathological examination. This case suggests that irinotecan has the potential to inhibit the growth of hepatic leiomyosarcomas. The possibility of comorbid different histological types of tumors should be suspected when considering the treatment of multiple liver tumors. Primary hepatic leiomyosarcoma is a particularly rare tumor with a poor prognosis. Curative resection is currently the only effective treatment, and the efficacy of chemotherapy is unclear. This represents the first case report of a patient with primary hepatic leiomyosarcoma co-existing with metastatic liver carcinoma. We present a 59-year-old man who was diagnosed preoperatively with rectal cancer with multiple liver metastases. He underwent a curative hepatectomy after a series of chemotherapy regimens with modified FOLFOX6 consisting of 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab, FOLFIRI consisting of 5-fluorouracil, leucovorin and irinotecan plus bevacizumab, and irinotecan plus cetuximab. One of the liver tumors showed a different response to chemotherapy and was diag-nosed as a leiomyosarcoma following histopathological examination. This case suggests that irinotecan has the potential to inhibit the growth of hepatic leiomyosarcomas. The possibility of comorbid different histological types of tumors should be suspected when considering the treatment of multiple liver tumors.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第38期5479-5484,共6页 世界胃肠病学杂志(英文版)
关键词 Leiomyosarcoma Rectal cancer Metastasis Chemotherapy Surgery 原发性 直肠癌 肝癌 肉瘤 病理组织学检查 肝脏肿瘤 化疗药物 氟尿嘧啶
  • 相关文献

参考文献13

  • 1Fong JA, Ruebner BH. Primary leiomyosarcoma of the liver. Hum Pathol 1974; 5:115-119.
  • 2Matthaei H, Krieg A, Schmelzle M, Boelke E, Poremba C,Rogiers X, Knoefel WT, Peiper M. Long-term survival after surgery for primary hepatic sarcoma in adults. Arch Surg 2009; 144: 339-344; discussion 344.
  • 3Shivathirthan N, Kita J, Iso Y, Hachiya H, Kyunghwa P, Sawada T, Kubota K. Primary hepatic leiomyosarcoma: Case report and literature review. World J Gastrointest Oncol 2011; 3:148-152.
  • 4Gates LK, Cameron AJ, Nagorney DM, Goellner JR, Farley DR. Primary leiomyosarcoma of the liver mimicking liver abscess. Am J Gastroenterol 1995; 90: 649-652.
  • 5Eriksson M. Histology-driven chemotherapy of soft-tissue sarcoma. Ann Oncol 2010; 21 Suppl 7: vii270-vii276.
  • 6Scurr M. Histology-driven chemotherapy in soft tissue sarcomas. Curr Treat Options Oncol 2011; 12:32-45.
  • 7Casey DA, Wexler LH, Merchant MS, Chou AJ, Merola PR, Price AP, Meyers PA. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pedi-atr Blood Cancer 2009; 53:1029-1034.
  • 8Mascarenhas L, Lyden ER, Breitfeld PP, Walterhouse DO, Donaldson SS, Paidas CN, Parham DM, Anderson JR, Meyer WH, Hawkins DS. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group. J Clin Oncol 2010; 28: 4658-4663.
  • 9Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, Belghiti J, Piedbois P, Guimbaud R, Nordlinger B, Bugat R, Lazorthes F, Bedenne L. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24: 4976-4982.
  • 10Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371:1007-1016.

同被引文献7

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部